Major Depressive Disorder

Psychiatric neurosurgery is not a first-line treatment for depression. Neuromodulation approaches, including DBS, remain a specialized and, in many settings, still-developing option, considered only for highly selected patients within structured multidisciplinary programs, alongside ongoing psychiatric care.

Major depressive disorder is a serious mental health condition causing persistent low mood, loss of interest or pleasure, and a range of other symptoms affecting sleep, energy, concentration and self-worth. The great majority of patients respond to standard treatment, medication, psychotherapy, and, for more severe or resistant cases, treatments such as electroconvulsive therapy (ECT) or repetitive transcranial magnetic stimulation (rTMS).

A small number of patients have depression that remains severe and disabling despite thorough, appropriately delivered treatment. For this group, neuromodulation approaches, including deep brain stimulation, are the subject of ongoing clinical use and research, and may be considered in highly selected cases within specialized programs.

Before any discussion of neurosurgical options, it is expected that a patient has had adequate trials of multiple classes of antidepressant medication, an appropriate course of evidence-based psychotherapy, and, where clinically appropriate and available, treatments such as ECT or rTMS. This treatment history is reviewed in detail, in coordination with the patient’s psychiatric team, as part of any evaluation.

We believe it is important to be direct about this: in many settings, the use of DBS and related neuromodulation approaches for depression remains a specialized and, in some respects, still-developing area of treatment, rather than an established first-line surgical option in the way that DBS is for Parkinson’s disease. Evidence continues to develop, response is variable between patients, and this pathway is appropriate only within a carefully structured, multidisciplinary program with realistic goals from the outset.

Evaluation is led jointly by psychiatry and neurosurgery, with input from neuropsychology. It focuses on confirming the diagnosis, excluding conditions that may mimic or complicate depression (including bipolar disorder, which needs to be assessed carefully beforehand), documenting genuine treatment resistance, and assessing psychiatric stability, safety and the capacity to engage in a lengthy structured evaluation and follow-up process.

A surgical evaluation is considered only for adult patients with confirmed, severe, treatment-resistant major depressive disorder, following the treatment history described above, and only after joint review and agreement between the patient’s treating psychiatric team and a specialist multidisciplinary panel. This is approached with particular caution given the specialized and evolving nature of the evidence in this specific area.

Where DBS is considered appropriate for depression, it follows the same general surgical principles described on our Deep Brain Stimulation page: electrodes are placed in a brain target associated with mood-regulating circuits and connected to a programmable, adjustable pulse generator. Programming for depression is typically a long, incremental process, closely coordinated with the psychiatric team, and changes in mood related to stimulation are monitored particularly closely given the nature of the condition being treated.

Low-intensity focused ultrasound (LIFU) is a newer, investigational neuromodulation technique also being studied for treatment-resistant depression, alongside DBS. Unlike DBS, it involves no implant and no incision, and unlike MRgFUS, it does not create a permanent lesion; it aims to temporarily influence activity in a targeted brain circuit. We describe it here in deliberately cautious terms: the evidence for LIFU in depression is at an earlier stage than for DBS, and where it is offered, it is generally through specialized or research programs rather than as routine care. See the LIFU page for full detail, including how it differs from both DBS and MRgFUS.

• Independent, detailed psychiatric assessment confirming diagnosis and treatment history
• Careful exclusion of bipolar disorder and other conditions that would change the treatment approach
• Structured mood and safety assessment, including assessment of suicide risk
• Neuropsychological evaluation
• Brain MRI for surgical planning
• Joint multidisciplinary case review before any decision is made

We want to be clear rather than optimistic: for highly selected patients within a specialized program, the aim of neuromodulation is a meaningful reduction in the severity and disability of depression, alongside continued psychiatric care; not a promised cure, and not a guaranteed or rapid response. Response varies between patients and can take an extended period of programming and adjustment to become apparent, if it occurs at all. Setting realistic expectations before any decision is made is one of the most important parts of this evaluation.

Risks include the general surgical and hardware-related risks described on our Deep Brain Stimulation page, as well as the possibility that stimulation does not produce adequate improvement in mood. Because mood, motivation and safety can all be affected by stimulation itself, particularly close psychiatric monitoring is required during programming, including attention to any change in suicidal thinking.

Neuromodulation for depression does not replace psychiatric care. Medication, psychotherapy and regular psychiatric review continue after surgery, and programming is carried out jointly with the psychiatric team over an extended period, with safety monitoring built into every stage of follow-up.